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Abstract 
Lipopolysaccharide (LPS) endotoxins are widely used as experimental models of systemic bacterial infection and trigger robust inflammation by 
potently activating toll-like receptors 4 (TLR4) expressed on innate immune cells. Their ability to trigger robust neuroinflammation despite poor 
brain penetration can prove useful for the understanding of how inflammation induced by viral infections contributes to the pathogenesis of 
neurodegenerative diseases. A single LPS challenge often result in a blunted inflammatory response to subsequent stimulation by LPS 
and other TLR ligands, but the extent to which endotoxin tolerance occur in the brain requires further clarification. LPS is also thought to 
render the brain transiently resistant to subsequent brain injuries by attenuating the concomitant pro-inflammatory response. While LPS 
hyporesponsiveness and preconditioning are classically seen as protective mechanisms limiting the toxic effects of sustained inflammation, 
recent research casts doubt as to whether they have beneficial or detrimental roles on the brain and in neurodegenerative disease. These 
observations suggest that spatio-temporal aspects of the immune responses to LPS and the disease status are determinant factors. 
Endotoxin tolerance may lead to a late pro-inflammatory response with potential harmful consequences. And while reduced TLR4 signaling 
reduces the risk of neurodegenerative diseases, up-regulation of anti-inflammatory cytokines associated with LPS hyporesponsiveness 
can have deleterious consequences to the brain by inhibiting the protective phenotype of microglia, aggravating the progression of some 
neurodegenerative conditions such as Alzheimer’s disease. Beneficial effects of LPS preconditioning, however appear to require a stimulation 
of anti-inflammatory mediators rather than an attenuation of the pro-inflammatory response. 
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 Introduction 
Lipopolysaccharide (LPS) endotoxins, the major outer 
membrane components of Gram-negative intestinal micro-
biota, are potent activators of innate immunity, and as 
such widely used as experimental models of systemic 
bacterial infections. LPS typically consists in lipid A and 
polysaccharides or oligosaccharides, with the saccharides 
element being diverse in length and composition amongst 
the different Gram-negative bacteria species [1]. Lipid A 
molecules trigger the biosynthesis of diverse mediators of 
inflammation by potently activating toll-like receptors 4 
(TLR4) expressed on innate immune cells, but other 
proteins, including TLR2, also bind LPS with minimal 
contribution to its effects [2]. TLR4 are part of the large 
mammalian TLRs family consisting of at least 11 receptors 
in human and 13 in mice. They are expressed on most 
tissues [3] predominantly on immune cells, thereby playing 
a crucial role in the control of the immune response to 
pathogens [4]. 
In the central nervous system (CNS), all cell types, 
including neurons, express at least one TLR, but microglia, 
the resident immune cell of the brain, expresses the whole 
repertoire and TLR4 selectively [5–7]. Microglial activation 
is a hallmark of brain pathology, which contributes to the 
neuroinflammation-related neuronal injury in neurodege-
nerative diseases when prolonged and/or uncontrolled, 
while also having beneficial effects through its phago-
cytotic phenotype [8–10]. Thus, by targeting microglia, 
LPS can be seen as model of choice for the understanding 
of the complex interplay between infection, compromised 
microglial function, neuroinflammation and neurodege-
neration in brain diseases, but its poor brain penetration 
upon systemic administration has to be taken into account 
[11]. Systemic LPS administration nevertheless induces 
robust microglial activation and neuroinflammation [12]. 
Understanding how can provide new insights into the 
emerging view that inflammation resulting from viral 
infections is a trigger of the clinical onset of neurodege-
nerative diseases [13, 14]. 
To model chronic inflammation, repeated LPS admi-
nistrations would be an appealing approach, but LPS 
hyporesponsiveness, also called “endotoxin tolerance” 
[15], is a frequent outcome also induced by genetic 
mutations of TLR4 [16, 17]. The concept of endotoxin 
tolerance was developed after the observation that pre-
exposure to a sublethal dose of LPS markedly reduced 
mortality in animals re-challenged with a lethal dose of 
LPS while also inducing cross-tolerance to others TLRs 
ligands [18, 19]. Endotoxin tolerance is observed in the 
clinical settings [19] where its implications for a range 
of inflammatory conditions have been well described in 
most peripheral tissues, with both protective – enhanced 
resistance to sepsis and ischemia – and detrimental – 
increased risk of secondary infections in patients with 
non-infectious systemic inflammation response syndrome 
– consequences [19, 20]. Its impact on the brain, however, 
remains poorly understood. Endotoxin tolerance also 
manifest with transient protection to subsequent brain 
injuries resulting from the associated blunted neuro-
inflammatory response [21], but the occurrence of bene-
ficial effects of preconditioning with sub-lethal LPS doses 
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may be disease-dependent. Thus, the purpose of this review 
is to question the impact of endotoxin tolerance on the 
brain following systemic LPS administration and to shed 
light on the detrimental or beneficial roles that LPS hypo-
responsiveness and preconditionning may have in neuro-
degenerative diseases. To address these questions, it is 
important to focus on timing, therefore the time course 
of immune responses to LPS will first be investigated. 
 How do peripheral LPS trigger immune 
responses in the brain? 
LPS dose-dependently induces inflammation to severe 
sepsis associated with a sickness syndrome. The immune 
response to LPS response typically consists in the secretion 
of pro-inflammatory cytokines, including interleukins (IL, 
e.g., IL-1β, IL-6, IL-8, and IL-12), tumor necrosis factor 
alpha (TNF-α) and interferon gamma (IFN-γ); anti-inflam-
matory cytokines [e.g., IL-1 receptor antagonist (IL-1Ra), 
IL-4, IL-10, IL-13] secreted as feedback inhibitors to 
terminate the LPS response as well as acute phase proteins 
[e.g., C-reactive protein (CRP), serum amyloid A, serum 
amyloid P component]. IL-1β is classically seen as a 
signature of inflammation since it is normally present a 
very low levels and very rapidly induced in response to 
pro-inflammatory stimuli [22]. 
Upon systemic LPS administration, immune mediators 
are primarily synthesized in the periphery. They are also 
found in increased levels in the brain in response to LPS, 
but their origin is a matter of debate. There is indeed 
controversy as to whether LPS crosses the blood–brain 
barrier (BBB) and can mediate an immune response via 
direct stimulation of microglial TLR4. Brain concentrations 
of LPS were indeed found to be about 0.025% of intra-
venously administered doses per gram of tissue at two 
hours post-injection [11]. This suggests that transit of 
circulating cytokines across the BBB after LPS challenge 
is the most likely potential source of cerebral cytokines 
levels, indirectly inducing resident microglia to produce 
the same cytokines through a TLR4-independent mecha-
nism [23, 24]. The presence of TLR4 on CNS-resident 
cells, particularly perivascular hematopoietic cells, is 
however required for sustained neuroinflammation after 
systemic LPS administration independent of systemic 
cytokines [7]. Some cytokines can also be produced through 
direct microglial stimulation by LPS in brain structures 
devoid of BBB such as the circumventricular organs [25]. 
Moreover, LPS has been shown to increase BBB perme-
ability via binding to TLR4 in endothelial cells at the 
surface of blood vessels, indirectly activating adjacent 
microglia and potentially inducing late disruption of the 
BBB via some of the secreted cytokines (e.g., TNF-α, IL-1β) 
[26, 27]. A direct delayed stimulation of microglia by LPS 
can therefore be expected [7] and this process may be 
exacerbated in neurodegenerative diseases where the BBB 
is compromised [28]. 
The CNS mediates the sickness response to LPS, which 
is characterized by flu like-symptoms including reduced 
motivation for food and fluids, behavioral suppression, 
social withdrawal, hyperalgesia and changes in core body 
temperature (fever in human, often hypothermia in mice). 
These physiological and behavioral changes are considered 
a protective response designed to facilitate recovery from 
the infection [29]. Sickness behavior was long thought to 
be driven by the secreted pro-inflammatory cytokines, 
but its occurrence at LPS doses below the threshold for 
inducing inflammation and its advanced time course com-
pared to that of most circulating inflammatory mediators 
led to the proposal that other mechanisms, such as vagal 
nerve stimulation or blood-borne prostaglandin E2, contri-
bute to its onset [30, 31]. 
 When do brain immune responses occur 
after systemic LPS? 
The most comprehensive time courses come from 
studies in human healthy volunteers showing that LPS 
dose-dependently increases physiological indicators of 
sickness, and blood levels of cytokines and acute phase 
proteins. These experiments [32–38], summarized in 
Table 1, indicate that the inflammatory response to effective 
LPS doses (>0.3 ng/kg, i.v.) is transient, usually resolving 
within 24 hours, and biphasic with an early pro-inflam-
matory phase followed by an anti-inflammatory phase. 
The time course of the LPS response vary between 
individual symptoms, immune mediators and dose used 
(Table 1), but it can be concluded that (i) sickness 
symptoms initiate within one hour, peak between two 
and six hours and slowing resolve after 12 hours, (ii) 
circulating pro-inflammatory cytokines levels typically 
peak at 1.5–3.5 hours and resolve after 6–12 hours when 
levels of CRP levels start to gradually raise until at least 
24 hours post-LPS, while (iii) anti-inflammatory cytokines 
peak from two hours post-LPS administration and remain 
persistently and moderately elevated levels for at least 
eight hours post LPS. The most rapid changes are seen 
with TNF-α, which peaks first and start returning to 
baseline levels before other pro-inflammatory cytokines 
reach their peak response. 
Time course information in rodents are usually restricted 
to 2–4 time points, but tend to indicate that the peripheral 
(Table 2) and sickness (Table 3) responses to LPS follow 
a similar temporal pattern showing that (i) sickness 
behavior, with noticeable locomotor suppression during 
the dark-active phase of the circadian cycle and increase 
in body temperature during the light-inactive phase of the 
day, persists for over 24 hours, (ii) levels of pro-inflam-
matory cytokines are elevated between two and six hours 
post-injection, and (iii) levels of anti-inflammatory cyto-
kines appear to be more persistently elevated. 
The poor brain penetration of systemic LPS strongly 
argues in favor of a delayed brain immune response as 
compared to the periphery, but this cannot be determined 
with certainty as direct comparisons in rodents often include 
too few time points and quantify mRNA rather than 
protein levels of central immune mediators. Changes in 
mRNA levels can be induced very rapidly (Table 3), but 
it is unclear whether, and to which extent, they would later 
be translated into protein. Indeed, a recent in vitro study 
peripheral blood mononuclear cells incubated with the 
VLP (virus-like particle) influenza A virus showed that 
protein changes can only be predicted by mRNA levels 
for a limited number of the 20 cytokines and chemokines 
investigated [39]. The authors found that mRNA levels 
closely mirror protein levels for IFN-γ, MIP1A (macrophage 
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inflammatory protein-1alpha), IP10 (interferon gamma-
induced protein-10), and TNF-α; moderately parallel protein 
levels for IL-2, GM-CSF (granulocyte-macrophage colony-
stimulating factor), IL-5, RANTES (regulated upon acti-
vation, normal T-cell expressed and presumably secreted), 
and MCP1 (monocyte chemoattractant protein-1) but were 
unrelated to protein levels for the 11 other markers [IL-1A, 
IL-1B, IL-4, IL-6, IL-8, IL-10, IL-13, IL-17A, IL-17B, 
G-CSF (granulocyte-colony stimulating factor), and 
EOTAXIN]. The data reviewed in Tables 2 and 3, however 
allow to conclude that IFN-γ is only induced in the 
periphery, while IL-6 is the most responsive pro-inflam-
matory cytokine in both compartments. One study directly 
compared serum and whole brain cytokine levels in the 
same assay after a high non-lethal dose of 3 mg/kg of LPS 
[40], pointing towards a distinct time course in the brain 
rather than a delayed response. Indeed, while IL-10 showed 
a similar biphasic response in both compartments, charac-
terized by an early (within four hours) and late (after 24 
hours) increase, a delayed brain increase was observed for 
IL-1α, IL-1β and TNF-α, but the elevation in IL-6 levels 
was more persistent in the brain than in the blood [40]. 
Table 1 – Time course of sickness syndrome and peripheral immune mediators in healthy volunteers subjected to 
single and repeated LPS challenges 
 1 h 1.5 h 2 h 2.5 h 3 h 3.5 h 4 h 4.5 h 5 h 6 h 6.5 h 8 h 10 h 12 h 20 h 24 h Dose / Reference 
Sickness syndrome 
= ++ +++ + +  + + = =      = 2 ng/kg [34] 
= ++ ++ = =            2*2 ng/kg [34] 
= = + = =            3*2 ng/kg [34] 
= = = = =            4*2 ng/kg [34] 
Symptom 
scores 
= = = = =  = = = =       5*2 ng/kg [34] 
= = =  +  +++   +  = =  = = 0.5 ng/kg [32] 
= = ++  +++  +++   ++  + +  = = 1 ng/kg [32] 
= + ++ ++ +++ +++ +++ +++ ++ ++  + +  = = 2 ng/kg [32, 34, 41] 
= + ++              2*2 ng/kg [34] 
= = +              3*2 ng/kg [34] 
= = +              4*2 ng/kg [34] 
= = +  +  ++ ++ + +       5*2 ng/kg [34] 
Body 
temperature 
+ + ++ ++ +++ +++ +++ +++ +++ ++ ++ ++    + 4 ng/kg [33, 35] 
= = =  +  +++   +  + =  = = 0.5 ng/kg [32] 
= = +  +++  ++   ++  ++ +  = = 1 ng/kg [32] 
+ + +  ++  ++ +++ +++ +++  ++ +  = = 2 ng/kg [32, 34] 
=  =  +  ++ ++ + +       5*2 ng/kg [34] 
Heart rate 
= + ++ ++ +++ +++ +++ +++ +++ ++ ++ ++  ++  + 4 ng/kg [33, 35] 
Pro-inflammatory cytokines 
  +++    ++   +  + =    0.4 ng/kg [38] 
= = =  =  =   =       0.5 ng/kg [32] 
+ +++ +++  +  +   =       1 ng/kg [32] 
+ +++ +++  ++  +  + =  =     2 ng/kg [32, 34, 36, 37, 41] 
= = =    =   =       5*2 ng/kg [34] 
TNF-α 
+ ++ +++ +++  ++  ++   + +    = 4 ng/kg [33] 
IFN-γ + +++ ++  =  =          2 ng/kg [36] 
  +++    ++   =  = =    0.4 ng/kg [38] 
= = =  +++  =   =       0.5 ng/kg [32] 
= = +++  +++  =   =       1 ng/kg [32] 
= + +++  +++  +  = =  =     2 ng/kg [32, 34, 36, 37, 41] 
= = =    =   =       5*2 ng/kg [34] 
IL-6 
= + ++ +++  +++  +++   + +    = 4 ng/kg [33] 
= = =  +++  =   =       0.5 ng/kg [32] 
= = +++  +++  +   =       1 ng/kg [32] 
= + +++  +++  ++   =       2 ng/kg [32] 
IL-8 
= + ++ +++  +++  ++   + +    = 4 ng/kg [33] 
Anti-inflammatory cytokines 
= = =    +++   +  +     2 ng/kg [34, 37] 
IL-1Ra 
= = =    =   =       5*2 ng/kg [34] 
IL-4 = = ++  +++  +++  ++ +       2 ng/kg [41] 
= + +++  +++  +   +  +     2 ng/kg [34, 36, 37] 
IL-10 
= = =    =   =       5*2 ng/kg [34] 
+ ++ +++    ++   ++       2 ng/kg [34] 
TGF-β 
+ ++ ++    ++   ++       5*2 ng/kg [34] 
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 1 h 1.5 h 2 h 2.5 h 3 h 3.5 h 4 h 4.5 h 5 h 6 h 6.5 h 8 h 10 h 12 h 20 h 24 h Dose / Reference 
Acute phase proteins 
      =       +  ++ 0.5 ng/kg [32] 
      =       ++  +++ 1 ng/kg [32] 
=      =   =    ++  +++ 2 ng/kg [32, 34, 36] 
               ++++ 2*2 ng/kg [34] 
               +++ 3*2 ng/kg [34] 
               ++ 4*2 ng/kg [34] 
CRP 
= =  =  =  =    +    +++ 4 ng/kg [33] 
+++ denotes peak response regardless of the dose. Significant increase from control levels: +, up to 50% of the peak response; ++, above 50% 
of the peak response; =, non-significant change from pre-LPS levels or untreated controls. Estimated increased or decreased magnitude of 
the LPS response to a 2nd challenge is indicated in red: =, lack of LPS response; ++++, increased levels after a 2nd challenge; + or ++, 
magnitude of the LPS response compared to a single challenge with the same dose. References: [32] Dillingh et al. (2014); [33] Kümpers et al. 
(2009); [34] Draisma et al. (2009), up to 5*2 ng/kg at 24-hour intervals; [35] Lynn et al. (2003); [36] Kemna et al. (2005); [37] van den Boogaard 
et al. (2010); [38] Straub et al. (2002); [41] Clodi et al. (2008). IL: Interleukin; TNF-α: Tumor necrosis factor alpha; TGF-β: Transforming growth 
factor beta; IFN-γ: Interferon gamma; CRP: C-reactive protein. 
Table 2 – Time course of peripheral immune response to single and repeated systemic LPS challenges in healthy mice 
and rats 
 1 h 2 h 3 h 4 h 6 h 8 h 12 h 16 h 20 h 24 h 28 h Dose / Reference
Pro-inflammatory cytokines 
++ +++  = =       0.1 mg/kg [42, 43]
 +++      =    0.25 mg/kg [44] 
 +++   +     =  0.63 mg/kg [45] 
 +++   =       1 mg/kg [7] 
 +++   +     =  2.5 mg/kg [45] 
   +++  +  +   = 3 mg/kg [40] 
TNF-α 
   +++        3*3 mg/kg [40] 
 =   +++     =  0.63 mg/kg [45] 
  +++         0.5 mg/kg [46] 
  =         2*0.5 mg/kg [46] 
  =         3*0.5 mg/kg [46] 
 =   +++       1 mg/kg [7] 
IFN-γ 
 =   +++     =  2.5 mg/kg [45] 
   +++  +++  ++   = 3 mg/kg [40] 
IL-1α 
   +++        3*3 mg/kg [40] 
 +++          0.1 mg/kg [43] 
 +++      ++    0.25 mg/kg [44] 
  +++         0.5 mg/kg [46] 
  +         2*0.5 mg/kg [46] 
  +         3*0.5 mg/kg [46] 
 +++   =     =  0.63 mg/kg [45] 
 +++   +++       1 mg/kg [7] 
 +++   =     =  2.5 mg/kg [45] 
   ++  +  =   + 3 mg/kg [40] 
IL-1β 
   ++        3*3 mg/kg [40] 
= +++  = =       0.1 mg/kg [42, 43]
 +++      =    0.25 mg/kg [44] 
 +++   ++     +  0.63 mg/kg [45] 
 +++   ++ ++    +  2.5 mg/kg [45, 47]
   +++  =  =   = 3 mg/kg [40] 
IL-6 
   ++++        3*3 mg/kg [40] 
  +++         0.5 mg/kg [46] 
  =         2*0.5 mg/kg [46] 
  =         3*0.5 mg/kg [46] 
IL-12 
 ++   +++       1 mg/kg [7] 
Anti-inflammatory cytokines 
IL-1Ra  +++          0.1 mg/kg [43] 
 +++   +++     =  0.63 mg/kg [45] 
 +++   +++ +++    +  2.5 mg/kg [45, 47]
   +  =  +   +++ 3 mg/kg [40] 
IL-10 
   ++        3*3 mg/kg [40] 
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 1 h 2 h 3 h 4 h 6 h 8 h 12 h 16 h 20 h 24 h 28 h Dose / Reference
   ---  ---  ---   --- 3 mg/kg [40] 
IL-13 
   ---        3*3 mg/kg [40] 
+++ denotes peak response regardless of the dose or significantly elevated levels for single time points. Significant increase from control levels: 
+, up to 50% of the peak response; ++, above 50% of the peak response; =, non-significant change from control levels. Estimated increased 
or decreased magnitude of the LPS response to a 2nd challenge is indicated in red: =, lack of LPS response; ++++, increased levels after 
repeated non-lethal doses of LPS; +, ++, +++, magnitude of the LPS response compared to a single challenge with the same dose. References: 
[7] Chakravarty & Herkenham (2005); [40] Erickson & Banks (2011), 3*3 mg/kg within 24 hours and given at 0, 6 and 24 hours; [42] Teeling 
et al. (2010); [43] Skelly et al. (2013); [44] Chen et al. (2005); [45] Biesmans et al. (2013); [46] Püntener et al. (2012), 3*0.5 mg/kg at 24-hour 
intervals; [47] Schneiders et al. (2015). IL: Interleukin, TNF-α: Tumor necrosis factor alpha; IFN-γ: Interferon gamma. 
Table 3 – Time course of the central immune response to single and repeated LPS challenges in healthy mice and rats 
 1 h 1.5 h 2 h 3 h 4 h 6 h 8 h 12 h 16 h 20 h 24 h 28 h Dose / Reference
Sickness syndrome 
= = = = = = = = = = =  50 μg/kg [47] 
Locomotion 
= = = = = = -- -- -- -- --  2.5 mg/kg [47] 
+ ++ ++ ++ ++ ++ = - - = =  50 μg/kg [47] 
  ++          0.1 mg/kg [43] Body temperature 
+ ++ ++ ++ ++ ++ + -- = = ++  2.5 mg/kg [47] 
Pro-inflammatory cytokines 
TNF-α                            mRNA   +++          0.1 mg/kg [43] 
mRNA   =      +++    0.25 mg/kg [44] 
mRNA   +++   ++     =  0.63 mg/kg [45] 
mRNA   +++  +++        1 mg/kg [7, 48] 
mRNA     +++        2*1 mg/kg [48] 
protein           +++  2 mg/kg [49] 
mRNA       +++    =  2.5 mg/kg [47] 
protein   +++   +++     =  2.5 mg/kg [45] 
protein     =  =  =   + 3 mg/kg [40] 
protein     +++        3*3 mg/kg [40] 
IFN-γ                             protein    =         0.5 mg/kg [46] 
protein    =         2*0.5 mg/kg [46] 
protein    =         3*0.5 mg/kg [46] 
mRNA   =   =     =  0.63 mg/kg [45] 
mRNA     =        1 mg/kg [48] 
mRNA     =        2*1 mg/kg [48] 
mRNA   =   =     =  2.5 mg/kg [45] 
IL-1α                              protein     =  =  +++   = 3 mg/kg [40] 
protein     +++        3*3 mg/kg [40] 
IL-1β                              mRNA ++  +++  + +       0.1 mg/kg [42, 43]
mRNA   +++      =    0.25 mg/kg [44] 
protein    =         0.5 mg/kg [46] 
protein    +++         2*0.5 mg/kg [46] 
protein    ++         3*0.5 mg/kg [46] 
mRNA   =   =     =  0.63 mg/kg [45] 
mRNA   +++  +++ +++       1 mg/kg [7, 48] 
mRNA     ++        2*1 mg/kg [48] 
protein            +++ 2 mg/kg [49] 
protein   =   +++     =  2.5 mg/kg [45] 
protein     =  =  =   +++ 3 mg/kg [40] 
protein     =        3*3 mg/kg [40] 
Pro-IL-1β                        mRNA       +++    +  2.5 mg/kg [47] 
IL-6                                mRNA =  +++  = =       0.1 mg/kg [42, 43]
mRNA   +++      =    0.25 mg/kg [44] 
mRNA   +++   ++     =  0.63 mg/kg [45] 
mRNA     +++        1 mg/kg [48] 
mRNA     +        2*1 mg/kg [48] 
protein            +++ 2 mg/kg [49] 
mRNA       +++    =  2.5 mg/kg [47] 
protein   +++   +++     =  2.5 mg/kg [45] 
protein     +  +  +   + 3 mg/kg [40] 
protein     +++        3*3 mg/kg [40] 
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 1 h 1.5 h 2 h 3 h 4 h 6 h 8 h 12 h 16 h 20 h 24 h 28 h Dose / Reference
IL-12                              protein    =         0.5 mg/kg [46] 
protein    +++         2*0.5 mg/kg [46] 
protein    =         3*0.5 mg/kg [46] 
Anti-inflammatory cytokines 
IL-1Ra                            mRNA     +++        1 mg/kg [48] 
mRNA     ++        2*1 mg/kg [48] 
mRNA       +++    +  2.5 mg/kg [47] 
IL-10                              mRNA   =   =     =  0.63 mg/kg [45] 
mRNA     +++        1 mg/kg [48] 
mRNA     +        2*1 mg/kg [48] 
mRNA   =   =     =  2.5 mg/kg [47] 
protein       +++    =  2.5 mg/kg [45] 
protein     +  =  =   + 3 mg/kg [40] 
protein     =        3*3 mg/kg [40] 
IL-13                              protein     =  =  =   = 3 mg/kg [40] 
protein     =        3*3 mg/kg [40] 
+++ denotes peak response regardless of the dose or significantly elevated levels for single time points. Significant changes from control 
levels: + or -, increase or decrease of up to 50% of the peak response; ++ or --, increase or decrease larger than 50% of the peak response; 
=, non-significant change from control levels. Estimated increased or decreased magnitude of the LPS response to a 2nd challenge is indicated 
in red: =, lack of LPS response; ++++, increased levels after a repeated non-lethal doses of LPS; +, ++, +++, magnitude of the LPS response 
compared to a single challenge with the same dose. References: [7] Chakravarty & Herkenham (2005), whole brain; [40] Erickson & Banks 
(2011), whole brain, 3*3 mg/kg within 24 hours and given at 0, 6 and 24 hours; [42] Teeling et al. (2010), dorsal hippocampus; [43] Skelly et al. 
(2013), hypothlamus and hippocampus; [44] Chen et al. (2005), whole brain; [45] Biesmans et al. (2013), whole brain; [46] Püntener et al. 
(2012), whole brain, 3*0.5 mg/kg at 24-hour intervals; [47] Schneiders et al. (2015), hypothalamus; [48] del Rey et al. (2009), hypothalamus, 
2*1 mg/kg at three weeks interval; [49] Cazareth et al. (2014), hypothalamus and hippocampus. IL: Interleukin, TNF-α: Tumor necrosis factor 
alpha; IFN-γ: Interferon gamma. 
 
In regard to the temporal response of glia, microglia 
are activated first and then recruit astrocytes to further 
propagate inflammatory signals and inhibit microglial 
activities [50]. The exact timing for these processes has 
not been studied in details. They are, however, thought to 
be largely mediated by IL-1β [50], which is induced in 
the brain during the early phase of the immune response 
(Table 3). These neuroinflammatory processes are also 
normally transient, with microglia returning to a resting 
state, as the immune stimulus is resolved. 
 LPS hyporesponsiveness or delayed pro-
inflammatory response? 
Recent findings cast doubt as to whether hypores-
ponsiveness occurs following repeated LPS challenges. 
Hyper-responsiveness develops under some circumstances, 
but more generally, the second LPS response rather seems 
distinct from the first occurrence, differing spatio-temporally 
and by the profile of secreted immune mediators. 
In human, endotoxin tolerance is typically studied 
ex vivo using blood cells from healthy volunteers pre-
exposed to LPS and subsequently incubated with LPS. 
Resulting data have to be taken with caution since non-
stimulated blood cells proliferate and produce cytokines 
[51] and tolerance to LPS was found to resolve faster 
ex vivo than in vivo [52]. But, interestingly, the cytokine 
response elicited by ex vivo re-exposure to LPS was found 
characterized by a reduction in the levels of pro-inflam-
matory cytokines (e.g., IL-1β, IL-6, and TNF-α) at six 
hours, which was followed by a sustained increased in the 
levels of these cytokines from 12 hours onwards, although 
IL-8 showed the opposite behavior [32]. Thus, this suggests 
that hyporesponsiveness to LPS occur in the early phase 
of the second challenge for some cytokines, when a 
reduction of the sickness syndrome associated with a 
attenuated increase in circulating pro- and anti-inflam-
matory cytokines levels is seen in vivo ([34], Table 1), but 
would be followed by a delayed, sustained pro-inflam-
matory reaction. 
In rodents, circulating levels of pro-inflammatory 
cytokines were found attenuated with repeated exposure 
to moderate LPS doses (0.5 mg/kg, [46]) but stable or 
increased with high non-lethal doses (3 mg/kg [40]). The 
latter could either be due to the high dose or differences in 
the dosing regimen but the protective effect of LPS against 
subsequent lethal doses (e.g., 32 mg/kg [44] suggests that 
the short inter-injection interval was responsible for the 
lack of tolerance. The second challenge was indeed applied 
six hours after the first when levels of pro-inflammatory 
cytokines are still significantly elevated (Table 2), possibly 
exacerbating the pre-existing inflammatory response. In 
contrast, Püntener et al. (2012) [46] have dosed at 24 hours 
intervals, during the anti-inflammatory phase of the LPS 
responses (Table 2), consistent with the view that anti-
inflammatory cytokines, IL-10 in particular, are the prin-
cipal mediators of endotoxin tolerance [21, 53]. 
 Does LPS hyporesponsiveness occur in 
the brain? 
Data summarized in Table 3 indicate that the brain is 
less likely to become tolerant to systemic infection than 
the periphery (Table 3). While the more severe dosing 
regimen (3×3 mg/kg within 24 hours) overall resulted in 
an exacerbated pro-inflammatory response, as was the case 
in the periphery (Table 2), LPS tolerance was cytokine-
dependent at milder doses and associated with reduced 
levels of anti-inflammatory cytokines (Table 3). Importantly, 
elevations in IL-1β and IL-6 were only seen three hours 
after the second 0.5 mg/kg LPS doses leading to the 
hypothesis that immune cells in the brain may be primed 
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instead [46]. This is in apparent contradiction with the 
recent report of significantly reduced production of multiple 
pro-inflammatory cytokines and chemokines, including 
IL-1β, TNF-α and IL-6, by microglia of mice receiving a 
second 0.25 mg/kg dose LPS injection after four weeks 
[48], but the inter-injection interval may have again contri-
buted to this discrepancy. 
Priming, which is typically observed in neurodegene-
rative diseases, refers to situations where microglia proli-
ferates and adopt an activated state, thereby becoming 
more susceptible to a secondary inflammatory stimulus, 
which will then exacerbate disease progression [54, 55]. 
Should repeated LPS doses prime the brain rather than 
inducing endotoxin tolerance, repeated systemic infections 
would thus has deleterious effects in susceptible indivi-
duals, predisposing to or exacerbating neurodegenerative 
conditions, despite peripheral tolerance [14, 46]. In favor 
of this hypothesis, repeated pro-inflammatory doses of 
LPS were found to aggravate pathological hallmarks of 
Alzheimer’s disease in transgenic mouse models. In the 
3xTg-AD mouse model, 0.5 mg/kg of LPS twice a week 
for six weeks exacerbated tau pathology while also indu-
cing persistent microglial activation and elevation of  
IL-1β but amyloid plaque load, IL-6 and TNF-α levels 
were unaltered [56]. Amyloid pathology is however also 
sensitive to LPS. Increased production of amyloid-beta and 
memory impairments were induced by repeated 0.250 mg/kg 
LPS doses in an APP/PS1 model, but although these 
effects were prevented by pretreatment with an anti-
inflammatory agent [57], the possibility that exacerbation 
of amyloid plaque load would result from LPS hypores-
ponsiveness also deserves some consideration, as will 
be discussed below. 
 Is LPS hyporesponsiveness protective to 
the brain? 
Evidence supporting a protective effect of LPS hypo-
responsiveness in Alzheimer’s disease comes from genetic 
association studies. The Asp299Gly polymorphism of the 
TLR4 gene, associated with an attenuated receptor signaling 
and a blunted inflammatory response, was found to reduce 
the risk of late onset Alzheimer’s disease by 2.7-fold [58] 
while a combination of polymorphisms in CD14 and 
LXRβ CD14 receptors known to lower the inflammatory 
responses of microglia to bacterial infection or LPS stimu-
lation, reduces the risk of developing the disease by 6-fold 
[59]. Furthermore, inflammatory cytokines levels correlate 
with amyloid load in the brain of transgenic mouse models 
of Alzheimer’s disease [60] suggesting that endotoxin 
tolerance can be protective to Alzheimer’s disease. However, 
although inflammatory processes are harmful to the disease, 
immune activation can also be beneficial by favoring 
microglial phagocytosis and clearance or amyloid-beta 
[10], leading to the contradictory hypothesis that LPS 
hyporesponsiveness would be detrimental during the course 
of Alzheimer’s disease. IL-10, the principal mediator of 
endotoxin tolerance thought to protect the brain from 
inflammatory damage induced by LPS by inhibiting the 
production of all inflammatory cytokines and down-
regulating TLR4 expression [21] was recently identified as 
an aggravating cytokine for Alzheimer’s disease, promoting 
amyloid deposition, synaptic dysfunction and cognitive 
impairments [61, 62]. Moreover, the pro-inflammatory 
cytokine IL-1β was found able to trigger microglial 
activation and reduce amyloid plaque pathology [63], while 
attenuating astrocyte activation accelerated plaque patho-
genesis in APP/PS1 mice [64]. Thus, whether LPS hypo-
responsiveness is beneficial or detrimental to Alzheimer’s 
disease appear dependent upon the disease status. It may 
limit the triggering impact of viral infections on disease 
onset in the healthy population and exacerbate disease 
progression once established by inhibiting the neuropro-
tective phenotype of microglia associated with neuro-
inflammation. 
Data from IL-6 deficient mice also suggest that LPS 
hyporesponsiveness is potentially detrimental to the brain. 
Direct inhibition of microglial IL-6 production facilitates 
recovery from LPS-induced sickness syndrome without 
altering circulating cytokine levels (IL-1β, IL-6, IL-10, 
TNF-α) [65]. IL-6 deficient mice, however, were found 
less responsive to LPS in the brain and blood during the 
acute phase of the immune response, with reduced secretion 
of pro-inflammatory cytokines and protection against LPS-
induced spatial working memory deficit [47, 66]. They 
were, however, more prone to inflammation in the brain at 
24 hours despite elevated IL-10 levels in both compart-
ments and attenuated peripheral pro-inflammatory response 
[47]. This suggests that LPS hyporesponsiveness can be 
associated with a delayed pro-inflammatory response to 
the brain which, and if sustained, harmful effects may 
occur [12]. 
 The spontaneously LPS-hyporesponsive 
C3H/HeJ mouse: protected or susceptible 
to neurodegenerative conditions? 
Inbred C3H/HeJ mice bear a loss of function in the 
TLR4 gene [67] making them refractory to LPS in the 
periphery because their macrophages do not produce pro-
inflammatory cytokines in response to LPS [68, 69], and 
in the brain because of a defect in microglia to induce 
pro-inflammatory cytokines [70, 71]. Intracerebral LPS 
administration fail to induce pro-inflammatory cytokines 
in the brain and blood of C3H/HeJ mice [72], or behavioral 
sickness symptoms, which can nevertheless be triggered 
by an intracerebral IL-1β challenge [73]. Furthermore, the 
resistance of C3H/HeJ mice to LPS is associated with 
increased susceptibility to bacterial infections [74] and 
may thus be restricted to TLR4 ligands. 
Consistent with their LPS-resistant phenotype, C3H/HeJ 
mice were found protected from conditions associated with 
low-grade inflammation, such as obesity and insulin-
resistance induced by high fat diet [69, 75], which are 
known to be predominantly mediated by TLR4 [76, 77]. 
Interestingly, these metabolic conditions are established 
risks factors for Alzheimer’s disease [78], suggesting 
that C3H/HeJ mice may be protected from age-related 
Alzheimer’s-like changes. Under non-stimulated condi-
tions, hippocampal neurogenesis also differs in adult 
C3H/HeJ mice as they produce more neurons and less 
astrocytes than control mice [79]. Therefore, one may 
expect resistance to neuroinflammation in these mice, as 
well as preserved cognitive ageing, but the fact that they 
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carry the retinal neurodegeneration mutation makes the 
latter difficult to assess [80]. There is, however, evidence 
to suggest that the C3H/HeJ mouse is not protected from 
neuroinflammation when mediated by stimuli other than 
TLR4 agonists. For instance, up-regulation of pro-inflam-
matory transcripts, including IL-1β, were found primarily 
around the blood vessels of both WT and C3H/HeJ mice 
exposed to commercially available LPS, but C3H/HeJ mice 
were refractory to inflammation induced by purified LPS, 
suggesting that they can mount a pro-inflammatory response 
in a TLR4 independent manner [7]. Non-LPS immune 
stimuli indeed activate microglia in the spinal cord [81] 
and hypothalamus of these mice while also inducing pro-
inflammatory cytokines levels [82]. And although C3H/HeJ 
mice are protected from brain damage and neuroinflam-
mation induced by experimental stroke [83], they were 
found more susceptible to prion diseases [84] and spinal 
cord injury [85], both of which also have an inflammatory 
component. 
 LPS preconditioning: protection or 
susceptibility to secondary injuries  
and neurodegenerative diseases? 
The benefits of LPS preconditioning have been parti-
cularly well documented for stroke, in which the acute 
inflammation triggered by cerebral ischemia exacerbates 
primary brain damage. Ischemic tolerance in the brain is 
contributed for by inhibition of TLR4 and pro-inflam-
matory cytokines, and bears striking similarities with 
endotoxin tolerance [21]. A single pre-treatment with a 
very low 50 μg/kg dose of LPS 24 hours before inducing 
focal cerebral ischemia limited the extent of vascular 
injury and infarct volume too [86]. Persistent protective 
effects on infarct volume associated with reduced micro-
glial activation and secretion of pro-inflammatory cytokines 
are commonly found at higher pro-inflammatory doses up 
to 200 μg/kg [87]. Higher acute LPS doses (0.2–1 mg/kg) 
administered 72 hours prior to middle cerebral artery 
occlusion, also had protective effects involving redirection 
of TLR signaling with an increased anti-inflammatory 
phenotype which was, paradoxically, not associated with 
a suppression of the pro-inflammatory response [88, 89]. 
A significantly more severe pre-treatment regimen (four 
daily 1 mg/kg LPS doses) also attenuated lesion volume 
and apoptosis after cryogenic brain injury while conco-
mitantly increasing proliferation of microglia [23], which 
may have thus become primed. This suggests that the 
beneficial effects of LPS preconditioning are predomi-
nantly mediated by a stimulation of anti-inflammatory 
mediators. 
In contrast, LPS can be neurotoxic in brain areas 
innervated by the dopaminergic system, particularly the 
substantia nigra, where microglial activation and its neuro-
toxic products, including pro-inflammatory cytokines, are 
thought to play an essential role in dopaminergic neuro-
degeneration during the pathogenesis of Parkinson’s disease 
[90]. Intra-nigral administration of LPS leading to localized 
microgliosis was accompanied by nigrostriatal neurode-
generation and stable spontaneous motor deficits [91]. 
Furthermore, intra-nigral injection of a low dose of LPS, 
which increased pro-inflammatory cytokines levels and 
reduced anti-inflammatory cytokines levels in the substantia 
nigra, exacerbated the magnitude of cell loss produced 
by subsequent intra-striatal injection of the neurotoxin 
6-hydroxydopamine (6-OHDA) [92], indicating that these 
areas of the brains are resistant to the anti-inflammatory 
effects of LPS preconditioning. 
 Conclusions 
Neuroinflammation resulting from systemic viral 
infection can play an important role in the development 
of neurodegenerative diseases. This can be modeled using 
LPS endotoxin through stimulation of TLR4 expressed 
on immune cells, triggering robust neuroinflammation, 
despite poor brain penetration. Tolerance to LPS and other 
TLR ligands, mediated by an up-regulation of anti-inflam-
matory cytokines, typically develop upon repeated LPS 
stimulation, and is considered as a protective response. 
The observations presented above, however, point towards 
a distinct response, involving a delayed pro-inflammatory 
reaction, rather than a blunted inflammatory response. 
Endotoxin tolerance is also less likely to occur in the brain 
than in the periphery conferring susceptibility to neuro-
degenerative diseases, the risk of which is reduced by 
attenuated TLR4 signaling. LPS hyporesponsiveness can, 
however, have deleterious effects in the brain, whereby anti-
inflammatory cytokines inhibit the protective phenotype of 
microglia, resulting in exacerbation of some neurodege-
nerative conditions such as Alzheimer’s disease. Beneficial 
effects of LPS preconditioning, on the contrary, appear to 
require a stimulation of anti-inflammatory mediators rather 
than an attenuation of the pro-inflammatory response. 
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